Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 158

Similar articles for PubMed (Select 21782065)

1.

Allogeneic stem cell transplantation in mantle cell lymphoma: where are we now and which way should we go?

Le Gouill S, Mohty M, Guillaume T, Gastinne T, Moreau P.

Semin Hematol. 2011 Jul;48(3):227-39. doi: 10.1053/j.seminhematol.2011.03.009. Review.

PMID:
21782065
2.

Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.

Gutiérrez-Aguirre CH, Ruiz-Argüelles G, Cantú-Rodríguez OG, González-Llano O, Jaime-Pérez JC, García-Rodríguez F, López-Otero A, Herrera-Garza JL, Gómez-Almaguer D.

Ann Hematol. 2010 Oct;89(10):1045-52. doi: 10.1007/s00277-010-0986-1. Epub 2010 May 21.

PMID:
20490794
3.

Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation.

Cook G, Smith GM, Kirkland K, Lee J, Pearce R, Thomson K, Morris E, Orchard K, Rule S, Russell N, Craddock C, Marks DI; Clinical Trials Committee (CTC) of the British Society for Blood and Marrow Transplantation (BSBMT).

Biol Blood Marrow Transplant. 2010 Oct;16(10):1419-27. doi: 10.1016/j.bbmt.2010.04.006. Epub 2010 Apr 24.

PMID:
20399879
4.

Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality.

Fenske TS, Zhang MJ, Carreras J, Ayala E, Burns LJ, Cashen A, Costa LJ, Freytes CO, Gale RP, Hamadani M, Holmberg LA, Inwards DJ, Lazarus HM, Maziarz RT, Munker R, Perales MA, Rizzieri DA, Schouten HC, Smith SM, Waller EK, Wirk BM, Laport GG, Maloney DG, Montoto S, Hari PN.

J Clin Oncol. 2014 Feb 1;32(4):273-81. doi: 10.1200/JCO.2013.49.2454. Epub 2013 Dec 16.

5.

Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience.

Le Gouill S, Kröger N, Dhedin N, Nagler A, Bouabdallah K, Yakoub-Agha I, Kanouni T, Bulabois CE, Tournilhac O, Buzyn A, Rio B, Moles MP, Shimoni A, Bacher U, Ocheni S, Milpied N, Harousseau JL, Moreau P, Leux C, Mohty M.

Ann Oncol. 2012 Oct;23(10):2695-703. Epub 2012 Mar 22.

7.

Reduced-intensity conditioning allogeneic stem cell transplantation in malignant lymphoma: current status.

Zhang L, Zhang YZ.

Cancer Biol Med. 2013 Mar;10(1):1-9. doi: 10.7497/j.issn.2095-3941.2013.01.001.

8.

Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia.

Blaise D, Vey N, Faucher C, Mohty M.

Haematologica. 2007 Apr;92(4):533-41. Review.

9.

Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.

Alvarez I, Sureda A, Caballero MD, Urbano-Ispizua A, Ribera JM, Canales M, García-Conde J, Sanz G, Arranz R, Bernal MT, de la Serna J, Díez JL, Moraleda JM, Rubió-Félix D, Xicoy B, Martínez C, Mateos MV, Sierra J.

Biol Blood Marrow Transplant. 2006 Feb;12(2):172-83.

PMID:
16443515
10.
11.

Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma.

Clavert A, Le Gouill S, Brissot E, Dubruille V, Mahe B, Gastinne T, Blin N, Chevallier P, Guillaume T, Delaunay J, Ayari S, Saulquin B, Moreau A, Moreau P, Harousseau JL, Milpied N, Mohty M.

Leuk Lymphoma. 2010 Aug;51(8):1502-8. doi: 10.3109/10428194.2010.497981.

PMID:
20583964
12.

Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).

Vigouroux S, Michallet M, Porcher R, Attal M, Ades L, Bernard M, Blaise D, Tabrizi R, Garban F, Cassuto JP, Chevalier P, Facon T, Ifrah N, Renaud M, Tilly H, Vernant JP, Kuentz M, Bourhis JH, Bordigoni P, Deconinck E, Lioure B, Socié G, Milpied N; French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).

Haematologica. 2007 May;92(5):627-34.

13.

Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy.

Khouri IF, Lee MS, Romaguera J, Mirza N, Kantarjian H, Korbling M, Albitar M, Giralt S, Samuels B, Anderlini P, Rodriguez J, von Wolff B, Gajewski J, Cabanillas F, Champlin R.

Ann Oncol. 1999 Nov;10(11):1293-9.

15.

Transplantation for non-Hodgkin lymphoma.

Nademanee A.

Expert Rev Hematol. 2009 Aug;2(4):425-42. doi: 10.1586/ehm.09.24. Review.

PMID:
21082947
16.

Allogeneic transplantation in lymphoma: current status.

Schmitz N, Dreger P, Glass B, Sureda A.

Haematologica. 2007 Nov;92(11):1533-48. Review.

17.

Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation.

Mohty M, Boiron JM, Damaj G, Michallet AS, Bay JO, Faucher C, Perreau V, Bilger K, Coso D, Stoppa AM, Tabrizi R, Gastaut JA, Michallet M, Maraninchi D, Blaise D.

Bone Marrow Transplant. 2004 Jul;34(1):77-84.

PMID:
15133485
18.

Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion.

Todisco E, Castagna L, Sarina B, Mazza R, Anastasia A, Balzarotti M, Banna G, Tirelli U, Soligo D, Santoro A.

Eur J Haematol. 2007 Apr;78(4):322-9. Epub 2007 Jan 23.

PMID:
17253967
19.

Incidence of Viral and fungal infections following busulfan-based reduced-intensity versus myeloablative conditioning in pediatric allogeneic stem cell transplantation recipients.

Satwani P, Baldinger L, Freedman J, Jacobson JS, Guerra J, van de Ven C, Morris E, Garvin J, George D, Bradley MB, Bhatia M, Tallamy B, Schwartz J, Jin Z, Cairo MS.

Biol Blood Marrow Transplant. 2009 Dec;15(12):1587-95. doi: 10.1016/j.bbmt.2009.08.006. Epub 2009 Sep 30.

PMID:
19896083
20.

Stem-cell transplantation for chronic lymphocytic leukemia: the 1999 perspective.

Dreger P, Michallet M, Schmitz N.

Ann Oncol. 2000;11 Suppl 1:49-53. Review.

PMID:
10707779
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk